NutritionCritical Health (Booth C3) Launches Innovative Diabetic Retinopathy Progression Biomarker Software Solution, RetmarkerDR, In The European Market
Critical Health will be launching RetmarkerDR, an innovative Diabetic Retinopathy (DR) progression biomarker software in the European market at the Euretina exhibition (Booth C3; 14th to 17th May; Acropolis Centre; Nice; France). Critical Health is a leading provider of innovative products that help prevent the loss of vision, mobility and cognitive skills in an ageing population.
Also at the 9th Euretina Congress, leading researchers from Critical Health"s partner AIBILI (Association for Biomedical Research and Innovation in Light and Image), will be presenting new research results that support this breakthrough in predicting Diabetic Retinopathy progression.
On the 14th of May, at Session 1 - Imaging to Monitor Progression, Professor Cunha-Vaz, AIBILI, will be presenting "The importance of monitoring progression in the early stages of retinal disease", to be followed by Professor Bernardes, Director of the Center of New Technologies for Medicine - AIBILI, regarding "Retmarker. Identifying progression on fundus images".
The RetmarkerDR software solution is a breakthrough in predicting Diabetic Retinopathy progression from a Nonproliferative stage to Clinically Significant Macular Edema (CSME), a sight-threatening stage. The solution is based on the latest research on Microaneurysm Turnover, the new and most reliable biomarker of Diabetic Retinopathy progression.
"This solution will become a critical tool to support ophthalmologists worldwide in the search for optimal management of diabetic retinopathy progression", said Ricardo Cunha-Vaz, Critical Health"s CEO. "RetmarkerDR helps to deliver quality care and to reduce total healthcare spending by increasing the healthcare provider"s productivity and reliability in the management of Diabetic Retinopathy and other retinal diseases".
The RetmarkerDR solution underlying approach is supported by recent leading edge research being presented by AIBILI at the most important scientific forums. Recently, two scientific papers supporting the RetmarkerDR technology were accepted for publication in the Ophthalmologica magazine and posters were presented at ARVO, in Fort Lauderdale, Florida, USA. The main conclusions of these studies are: Microaneurysm Turnover (more than just MA count) is a key indicator for the progression of Diabetic Retinopathy. RetmarkerDR is a reliable software tool which can be used to capture the MA turnover in the initial stages of DR.
For more information please visits http://www.retmarker.com
Critical Health